Join +750K new investors every month who copy stock picks from billionaire's portfoliosSign Up Free

Imugene advances to higher dosage level in Phase 1 clinical trial of new oncolytic virus VAXINA

Published 11/11/2022, 02:00 pm
Updated 11/11/2022, 02:30 pm
© Reuters.  Imugene advances to higher dosage level in Phase 1 clinical trial of new oncolytic virus VAXINA
CHRT
-

Imugene Ltd (ASX:IMU, OTC:IUGNF) has successfully progressed to the next stage of its Phase 1 clinical trial evaluating the safety of novel cancer-killing virus CF33-hNIS (VAXINIA) in metastatic advanced solid tumours (MAST).

The company will now open cohort 2 for intravenous (IV) administration, having cleared IV cohort 1 and following on from the first patient being dosed as part of the intra-tumoral (IT) cohort 2 of the trial in October.

The Cohort Review Committee (CRC) again unanimously confirmed VAXINIA to be safe, with no dose-limiting toxicities (DLTs) and no serious adverse reactions observed after the CRC reviewed all safety and tolerability data for the first three IV patients with the lowest dose of VAXINIA as monotherapy.

At completion of the review meeting, the CRC advised Imugene to proceed with opening the second VAXINIA Phase 1 IV cohort at the mid-dose level.

Positive momentum continues

“The MAST trial for VAXINIA has continued its positive momentum unimpeded to date, and again this is a credit to Imugene’s management,” Imugene managing director and CEO Dr Leslie Chong said.

“This momentum should be maintained with additional sites and broader patient recruitment as we move toward the new year.”

Once patients in the monotherapy group have been treated with the lowest doses of VAXINIA to the satisfaction of safety requirements, new study participants will receive it in combination with the immunotherapy pembrolizumab.

Imugene expects this phase of testing to begin following cohort 2 being cleared per route of administration.

Overall, the study aims to recruit up to 100 patients across some 10 trial sites in the United States and Australia.

Read more on Proactive Investors AU

Disclaimer

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.